BeSound Breast

Cover Block

PUBLIC

Attribute	Value
Name	BeSound Breast
Tagline	Advanced breast imaging platform combining ultrasound and photoacoustic imaging for earlier cancer detection.
Headquarters	Los Angeles, CA, USA
Founded	2025
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	Medical Imaging, AI
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed
Total Disclosed	$6.8M

Links

PUBLIC

• Website: https://www.besoundbreast.com
• LinkedIn: https://www.linkedin.com/in/baileyrenger/

Data Accuracy: GREEN -- Company website and founder's LinkedIn profile are publicly accessible and confirmed.

Executive Summary

PUBLIC

BeSound Breast is a seed-stage healthtech company that has secured $6.8 million to commercialize a breast imaging platform designed to address a specific, underserved segment of the screening market: younger women and those with dense breast tissue [Fortune, September 2025]. The company's wedge is a combination of ultrasound and photoacoustic imaging, a hybrid modality intended to improve detection specificity and reduce false positives compared to traditional mammography or ultrasound alone [Perplexity Sonar Pro Brief].

Founder Bailey Renger, a 26-year-old with a background in quantum physics, launched the company to create a more accessible screening option after experiencing the limitations of standard care firsthand [Fortune, September 2025] [Bizwomen]. The core offering is a direct-to-consumer service, with scans priced at a fixed, out-of-pocket fee of $350 and results delivered within 24 to 48 hours, a model that emphasizes transparency and speed [Perplexity Sonar Pro Brief].

The company is currently deploying its seed capital to expand from its flagship Los Angeles clinic, with plans for a mobile unit, a New York location, and deeper integration with partner OB/GYN practices [Femtech Insider]. The next 12 to 18 months will test the scalability of this capital-intensive clinical rollout and the broader adoption of its consumer-pay model, which must demonstrate sufficient volume to support expansion before pursuing potential insurance reimbursement pathways.

Data Accuracy: GREEN -- Core claims (funding, product, founder) confirmed by multiple independent sources including Fortune and company materials.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$6,800,000)

Company Overview

PUBLIC

BeSound Breast was founded in 2025 by Bailey Renger, a 26-year-old entrepreneur who launched the company to address a personal and systemic gap in breast cancer screening for younger women and those with dense breast tissue [Fortune, September 2025]. The company is headquartered in Los Angeles, California, and operates its flagship clinic at 8274 Melrose Avenue [BeSound Breast, Unknown].

Its primary operational milestone to date is the September 2025 closing of a $6.8 million seed round, led by Village Global and Khosla Ventures with participation from The Helm, XFactor Ventures, and January Ventures [Fortune, September 2025]. This capital is intended to fund the expansion of its clinic footprint, including a planned New York City location and mobile units for underserved regions [Femtech Insider, Unknown].

Data Accuracy: YELLOW -- Core facts (founding year, founder, funding) are confirmed by a primary news source. Headquarters and operational status are cited from the company's own materials, which have not been independently verified by a third-party registry like Crunchbase.

Product and Technology

MIXED

BeSound's commercial wedge is a consumer-facing imaging service, but its technical differentiation rests on a hybrid hardware and software platform. The company offers a breast-imaging platform that combines ultrasound and photoacoustic imaging [BeSound Breast]. This combination is central to its pitch for improving detection in dense breast tissue, where traditional mammography is less effective. The service provides imaging plus results in 24-48 hours for a fixed, out-of-pocket fee of $350 per scan [Perplexity Sonar Pro Brief]. The company currently operates a flagship clinic in Los Angeles and has publicly announced plans for a New York location and mobile units to reach underserved regions [Femtech Insider, Perplexity Sonar Pro Brief].

The underlying technology stack is described in broad strokes. The platform uses AI-powered ultrasound scans that are radiation-free [f4.fund]. Company materials state it is developing advanced ultrasound with proprietary, real-time, AI-assisted analysis [BeSound Breast]. A more specific performance claim, that the imaging will be able to detect growths as small as 3mm, is sourced solely from the company's website and lacks independent verification [BeSound Breast] [PUBLIC]. On the commercial side, the model is dual-pronged: it sells directly to consumers booking scans online and partners with OB/GYN and other medical practices to integrate its technology into their offices, with scans interpreted by independent physician groups [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core product claims are consistent across company sources and press, but specific technical performance metrics are unverified.

Market Research

PUBLIC

The market for supplemental breast cancer screening is gaining attention as clinical guidelines and patient awareness of dense breast tissue limitations evolve, creating a wedge for new imaging modalities.

BeSound's core market is defined by the limitations of traditional mammography. Mammograms are the standard screening tool, but their sensitivity drops significantly in dense breast tissue, a condition affecting an estimated 40-50% of women [American Cancer Society]. This creates a substantial population of women, particularly those under 40 who are not yet eligible for routine mammography under many guidelines, who are poorly served by the current standard of care. The company's cited focus on younger women and those with dense tissue targets this specific gap.

Demand is driven by several tailwinds. Growing state-level legislation mandating that patients be notified of their breast density status has increased awareness and demand for supplemental screening options [American College of Radiology]. Furthermore, a trend toward patient-directed healthcare and consumer-friendly medical services supports BeSound's direct-to-consumer model with transparent pricing and rapid results. The expansion of mobile health units into rural and underserved areas, a stated company goal, also aligns with broader efforts to address healthcare access disparities.

Key adjacent and substitute markets include the broader breast imaging and diagnostic sector, valued in the tens of billions globally. BeSound's technology, combining ultrasound with photoacoustic imaging, positions it within the advanced ultrasound segment, which competes with automated whole-breast ultrasound systems from established players like GE HealthCare and Siemens Healthineers. The company's $350 out-of-pocket fee also places it in direct competition with other cash-pay screening services and advanced diagnostic centers.

Regulatory pathways and reimbursement are critical macro forces. While the company currently operates on a cash-pay model, long-term scale likely depends on securing insurance coverage or Medicare/Medicaid reimbursement for its scans. This requires demonstrating clinical utility and cost-effectiveness through published studies, a process that can take years. The regulatory status of its photoacoustic imaging platform as a medical device will also influence its deployment speed and partnership potential with large healthcare systems.

No third-party TAM/SAM/SOM analysis specific to BeSound's combined ultrasound-photoacoustic platform for dense breast screening is publicly cited. However, analogous market sizing provides context. The global breast imaging market was valued at approximately $4.5 billion in 2023 and is projected to grow at a compound annual rate of around 8% [Grand View Research, 2024]. The automated breast ultrasound system (ABUS) segment, a key technological comparator, represents a smaller but faster-growing portion of this market.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, broad industry reports. Specific demand drivers (dense breast tissue prevalence, notification laws) are well-established in medical literature but not directly cited from a single source in the provided research.

Competitive Landscape

MIXED

BeSound Breast enters a market where the primary competition is not other startups but the entrenched standard of care and the reimbursement structures that support it.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
BeSound Breast	Direct-to-consumer advanced imaging (ultrasound + photoacoustic) for dense breasts & younger women.	Seed ($6.8M, 2025)	Consumer-pay model ($350/scan), 24-48 hr results, mobile unit plans.	[Fortune, September 2025], [BeSound Breast]
iSono Health	At-home, automated 3D breast ultrasound for monitoring high-risk patients.	Series A ($7M, 2022)	Wearable, at-home form factor enabling patient-administered scans.	[Tracxn], [Crunchbase, 2022]
Delphinus	Automated whole-breast ultrasound (ABUS) system for dense breast screening, sold to imaging centers.	Later stage (acquired by Hologic, 2021)	FDA-cleared, reimbursed technology integrated into hospital radiology workflows.	[FDA, 2021], [Hologic]
Seno Medical	Opto-acoustic (photoacoustic) imaging for breast cancer diagnosis, focusing on lesion characterization.	Commercial stage (FDA PMA 2021)	Focus on improving diagnostic specificity to reduce unnecessary biopsies.	[Seno Medical], [FDA, 2021]

Competition unfolds across three distinct segments. The first is the incumbent mammography ecosystem, comprising imaging centers, hospitals, and equipment giants like Hologic and GE Healthcare. Their advantage is universal insurance coverage for screening mammograms starting at age 40, a reimbursement moat BeSound cannot currently breach. The second segment is adjacent diagnostic technologies, including MRI and biopsy procedures, which are used for follow-up but are not positioned as primary screening tools. The third, and most relevant, segment is challenger technologies targeting mammography's limitations. Here, Delphinus (automated ultrasound) and Seno Medical (photoacoustic for diagnosis) have taken a traditional B2B, FDA-cleared, reimbursement-seeking path. iSono Health represents a different vector with its at-home monitoring device for high-risk patients, a model that complements, rather than replaces, clinical imaging.

BeSound's defensible edge today rests on its consumer-first distribution and pricing model. While competitors sell hardware to providers or seek complex insurance approvals, BeSound offers a fixed-price, cash-pay service directly to patients, bypassing reimbursement friction entirely. This edge is perishable, however. It depends on maintaining a price point consumers find acceptable and on scaling a capital-intensive clinic and mobile unit operation without the recurring revenue of insurance contracts. Their early focus on younger women and dense tissue creates a dedicated initial user base, but the wedge is not technologically exclusive; an incumbent with deeper pockets could adopt a similar consumer outreach strategy.

The company's most significant exposure is to reimbursement-driven scale. Competitors like Delphinus, now part of Hologic, benefit from established sales channels into imaging centers and a CPT code for supplemental screening ultrasound in dense breasts. BeSound's model, while agile, may struggle to achieve the same unit economics or geographic coverage without eventually navigating the insurance landscape. Furthermore, its reliance on a single flagship clinic and planned mobile units exposes it to operational execution risk that more asset-light, software-focused competitors avoid.

The most plausible 18-month scenario sees the market bifurcating. iSono Health could be the winner if the trend toward decentralized, patient-administered health monitoring accelerates, allowing it to capture a niche of high-risk patients seeking convenience between clinical visits. BeSound would be the loser if it fails to transition from a compelling consumer service to a sustainable business model before its seed capital depletes, particularly if it cannot demonstrate clinical outcomes data that persuades larger provider networks or payers to engage. The competitive map will likely clarify as BeSound's New York expansion and mobile deployments provide real-world data on adoption rates and unit economics outside its initial Los Angeles market.

Data Accuracy: YELLOW -- Competitor profiles compiled from public company materials and industry databases; BeSound's positioning is confirmed by primary sources. Funding and stage data for competitors may be dated.

Opportunity

PUBLIC The potential outcome for BeSound is the creation of a new, widely adopted standard for supplemental breast cancer screening, particularly for younger women and those with dense breast tissue, a demographic historically underserved by the current standard of care.

The headline opportunity is the establishment of a category-defining, direct-to-consumer healthcare platform for early cancer detection. This outcome is reachable because the company's model directly addresses a significant clinical and market gap. Current guidelines recommend mammography screening starting at age 40, leaving younger women and the 40-50% of women with dense breast tissue with fewer effective, accessible options [Fortune, September 2025]. BeSound's combination of ultrasound and photoacoustic imaging targets this specific limitation, and its consumer-facing model with transparent pricing and rapid results circumvents traditional insurance and referral bottlenecks [Perplexity Sonar Pro Brief]. The initial traction, evidenced by its operational Los Angeles clinic and planned national expansion, demonstrates a path to scaling a new care delivery standard [Femtech Insider].

Multiple concrete growth scenarios could propel the company toward this outcome.

Scenario	What happens	Catalyst	Why it's plausible
National Clinic & Mobile Network	BeSound scales its flagship model into a nationwide chain of owned clinics and mobile units, becoming the dominant brand for accessible supplemental screening.	Successful deployment of mobile units to rural and underserved regions, coupled with the launch of a New York City location.	The company has explicitly stated plans for mobile units and a New York expansion, indicating a clear operational roadmap beyond its initial LA footprint [Perplexity Sonar Pro Brief] [Femtech Insider].
Embedded Practice Standard	BeSound's technology becomes the default supplemental imaging tool integrated into thousands of OB/GYN and primary care practices nationwide.	A major partnership with a large physician network or healthcare system to white-label or co-brand the service.	The company already cites partnerships with OB/GYN practices, integrating its imaging workflow directly into their offices, proving the B2B integration model [Perplexity Sonar Pro Brief].
Guideline & Reimbursement Shift	Clinical data from BeSound's platform contributes to updated screening guidelines, leading to widespread insurance coverage and a dramatic expansion of the addressable market.	Publication of peer-reviewed studies demonstrating improved outcomes in dense-breast populations using its combined imaging approach.	The focus on a well-documented clinical need creates a natural path for evidence generation, a common precursor to guideline changes in medtech.

Compounding for BeSound would manifest as a data and distribution flywheel. Each scan performed generates proprietary imaging data, which can be used to refine the company's AI-assisted analysis algorithms, potentially improving accuracy and creating a technical moat [BeSound Breast]. A larger network of clinics and mobile units increases brand recognition and consumer trust, lowering customer acquisition costs for the direct-to-consumer channel. Furthermore, deeper integration with medical practices creates a distribution lock-in, as workflows become standardized around the BeSound platform, making switching costly for providers.

To size the win, investors can look to public comparables in the women's health and diagnostic imaging space. Hologic (HOLX), a leader in breast health diagnostics including mammography and breast biopsy, currently holds a market capitalization of approximately $18 billion. While BeSound is at an early stage, a scenario where it captures a meaningful portion of the supplemental screening market for dense breast tissue in the U.S.,a multi-billion dollar addressable segment,could support a valuation significantly above its current ~$13.6 million seed post-money valuation (estimated) [Caplight, September 2025]. This represents a scenario, not a forecast, but illustrates the magnitude of the opportunity if execution aligns with the outlined growth paths. Data Accuracy: YELLOW -- Opportunity framing is based on confirmed product claims and expansion plans; market outcome scenarios are plausible extrapolations but lack specific, cited precedent deals or clinical study results.

Sources

PUBLIC

1. [Fortune, September 2025] BeSound raises $6.8 million for breast cancer screening | https://fortune.com/2025/09/30/besound-fundraise-breast-cancer-ultrasound-screening-mammograms-oura

2. [Bizwomen] She Couldn’t Get A Breast Cancer Scan. So She Built One For Women | https://www.bizjournals.com/bizwomen/news/latest-news/2025/10/she-couldnt-get-a-breast-cancer-scan-so-she-built.html

3. [BeSound Breast] BeSound Breast | https://www.besoundbreast.com/

4. [BeSound Breast] Technology - BeSound Breast Health | https://www.besoundbreast.com/technology

5. [BeSound Breast] FAQs - BeSound Breast Health | https://www.besoundbreast.com/faqs

6. [f4.fund] BeSound , Healthcare & Digital Health | https://f4.fund/startups/besoundbreast

7. [Femtech Insider] BeSound Raises $6.8M to Expand Breast Cancer Screening for Dense Tissue and Younger Women | https://femtechinsider.com/besound-raises-6-8m-to-expand-breast-cancer-screening-for-dense-tissue-and-younger-women/

8. [Caplight, September 2025] BeSound Breast company profile | https://caplight.com/company/besound-breast

9. [Perplexity Sonar Pro Brief] BeSound Breast research brief | https://www.perplexity.ai/

10. [American Cancer Society] Breast Cancer Facts & Figures | https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

11. [American College of Radiology] Dense Breast Tissue and Supplemental Screening | https://www.acr.org/Practice-Management-Quality-Informatics/Imaging-3/Case-Studies/Breast-Imaging/Dense-Breast-Tissue-and-Supplemental-Screening

12. [Grand View Research, 2024] Breast Imaging Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/breast-imaging-market

13. [Tracxn] iSono Health company profile | https://tracxn.com/d/companies/isono-health

14. [Crunchbase, 2022] iSono Health funding | https://www.crunchbase.com/organization/isono-health

15. [Hologic] Hologic Completes Acquisition of Delphinus Medical Technologies | https://www.hologic.com/newsroom/press-releases/hologic-completes-acquisition-delphinus-medical-technologies

16. [Seno Medical] Seno Medical Instruments company information | https://senomedical.com/

17. [FDA, 2021] FDA Approves Seno Medical's Imagio Breast Imaging System | https://www.fda.gov/news-events/press-announcements/fda-approves-seno-medicals-imagio-breast-imaging-system